Revlimid receives expedited price listing in Japan for multiple myeloma
This article was originally published in Scrip
Executive Summary
Celgene's Revlimid (lenalidomide) has been given a reimbursement price in Japan for its lead indication of multiple myeloma, clearing the way for a commercial launch in this market.